UNSPSC 51411502: Cyclandelate

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4139O1OAY2. European Medicines Agency schedules Cyclandelate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06841MIG. Cyclandelate generally arises in the molecular formula C17H24O3.

UNSPSC 51411502 Cyclandelate (Commodity) represents pharmaceutical procurement by state and local governments, though recent activity under this code shows emergency medications and broader multi-source generics rather than cyclandelate specifically. State and local buyers soliciting under this code include city fire and rescue departments, state health agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work spans sealed-bid procurement of individual drug products with specific unit counts and expiration-date requirements, manufacturer direct-supply contracts with pharmacy benefit programs, and cooperative framework agreements for generic and over-the-counter pharmaceuticals distributed through authorized wholesalers. Vendors must meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and OSHA Safety Data Sheet requirements; larger cooperative contracts impose comprehensive insurance, EDI capability, and pricing-format flexibility obligations.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) to Tampa Fire Rescue with a response date of April 8, 2026 and an estimated contract value of $40,000.00; the bid included a 5 percent SLBE discount incentive and one-year term with two one-year renewal options. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendors with experience in direct contracts with self-insured employers and government agencies outside traditional PBM and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 with a March 26, 2026 response date for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness. No cyclandelate-specific procurement is evident in the recent record.